Neuland Laboratories Limited Total Liabilities
Neuland Laboratories Limited total liabilities. Based on the latest financial reports, Neuland Laboratories Limited (NEULANDLAB) has total liabilities worth Rs10.56 Billion INR (≈ $114.17 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Neuland Laboratories Limited's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Neuland Laboratories Limited (2006–2026)
Total liabilities of Neuland Laboratories Limited from 2006 to 2026. This chart illustrates how Neuland Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. Explore Neuland Laboratories Limited long-term investment allocation to see how much of total assets are deployed in long-term investments.
Neuland Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Neuland Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rede Energia Participações S.A
SA:REDE3
|
Brazil | R$28.79 Billion |
|
Boralex Inc
TO:BLX
|
Canada | CA$5.68 Billion |
|
Mandatum Oyj
HE:MANTA
|
Finland | €17.20 Billion |
|
Remitly Global Inc
NASDAQ:RELY
|
USA | $416.52 Million |
|
Hesai Group Sponsored ADR
NASDAQ:HSAI
|
USA | $2.05 Billion |
|
Bufab Holding AB
ST:BUFAB
|
Sweden | Skr5.12 Billion |
|
Tianneng Battery Group Co Ltd
SHG:688819
|
China | CN¥39.45 Billion |
|
AUB Group Ltd
AU:AUB
|
Australia | AU$2.77 Billion |
Liability Composition Analysis (2006–2026)
This chart breaks down Neuland Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NEULANDLAB asset base.
Liquidity & Leverage Metrics
Neuland Laboratories Limited Total Liabilities Ratios Explained
Neuland Laboratories Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuland Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuland Laboratories Limited (2006–2026)
The table below shows the annual total liabilities of Neuland Laboratories Limited from 2006 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs10.56 Billion ≈ $114.17 Million |
+61.15% |
| 2025-03-31 | Rs6.55 Billion ≈ $70.84 Million |
+19.14% |
| 2024-03-31 | Rs5.50 Billion ≈ $59.46 Million |
-6.11% |
| 2023-03-31 | Rs5.86 Billion ≈ $63.34 Million |
+7.86% |
| 2022-03-31 | Rs5.43 Billion ≈ $58.72 Million |
+0.87% |
| 2021-03-31 | Rs5.38 Billion ≈ $58.22 Million |
+3.32% |
| 2020-03-31 | Rs5.21 Billion ≈ $56.35 Million |
+20.87% |
| 2019-03-31 | Rs4.31 Billion ≈ $46.62 Million |
-16.03% |
| 2018-03-31 | Rs5.13 Billion ≈ $55.52 Million |
+51.00% |
| 2017-03-31 | Rs3.40 Billion ≈ $36.77 Million |
+0.76% |
| 2016-03-31 | Rs3.37 Billion ≈ $36.49 Million |
-3.57% |
| 2015-03-31 | Rs3.50 Billion ≈ $37.84 Million |
-2.60% |
| 2014-03-31 | Rs3.59 Billion ≈ $38.85 Million |
+10.59% |
| 2013-03-31 | Rs3.25 Billion ≈ $35.13 Million |
-7.03% |
| 2012-03-31 | Rs3.49 Billion ≈ $37.79 Million |
-0.74% |
| 2011-03-31 | Rs3.52 Billion ≈ $38.07 Million |
+6.93% |
| 2010-03-31 | Rs3.29 Billion ≈ $35.61 Million |
+10.57% |
| 2009-03-31 | Rs2.98 Billion ≈ $32.20 Million |
+33.75% |
| 2008-03-31 | Rs2.23 Billion ≈ $24.08 Million |
+59.28% |
| 2007-03-31 | Rs1.40 Billion ≈ $15.12 Million |
+47.24% |
| 2006-03-31 | Rs949.26 Million ≈ $10.27 Million |
-- |
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.